Schedule a Meeting
Download Brochure
Table of Content
April 2025
Principal Consultant
Reviewed By
The global diabetic neuropathy treatment market size is calculated at USD 4.71 in 2024, grew to USD 5.07 billion in 2025, and is projected to reach around USD 9.93 billion by 2034. The market is expanding at a CAGR of 7.75% between 2025 and 2034.
Over 90% of diabetic patients are affected by diabetic neuropathy, which is a type of complication associated with both types of diabetes. The main symptom is pain, and its mechanism is not fully known, but it is considered that it may be due to the toxic effects of hyperglycemia. The use of medications to alleviate pain and improve glycemic control as a prophylactic therapy is most commonly used in diabetic neuropathy management. The use of NSAIDs to reduce the pain is the first-line treatment option. Furthermore, the opioids use is also increasing. Similarly, capsaicin cream and lidocaine patches are also being used.
| Metric | Details |
| Market Size in 2024 | USD 4.71 Billion |
| Projected Market Size in 2034 | USD 9.93 Billion |
| CAGR (2025 - 2034) | 7.75% |
| Leading Region | North America |
| Market Segmentation | By Disorder Type, By Drug Class, By Distribution Channel and By Region |
| Top Key Players | Pfizer. Inc, Abbott, Janssen Pharmaceuticals, Inc, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd, Lupin Pharmaceuticals, Novartis, Astellas Pharma Inc, Boehringer Ingelheim GmbH |
By utilizing AI the diabetic neuropathy can be easily diagnosed and predicted. Thus, a new system was developed that helped in the diagnostic process. This system consisted of various parameters such as HbA1c levels, diabetes duration, fasting blood glucose, sign scores based on the Michigan questionnaire, symptom scores based on the Michigan questionnaire, proteinuria, and serum creatinine. The system also enhanced the accuracy during the diagnosis. Furthermore, models for glycemic management were also developed. These provided the clinicians a fast and accurate assessment of the patient's condition as well as in formulating the treatment plans.
Increasing Occurrences of Diabetes
The incidence of diabetes within the population is rising. This, in turn, increases the complications associated with it due to a lack of early detection. Thus, the demand for early detection as well as treatment options also increases. At the same time, the neuropathy also leads to worsening of the patient's condition. Hence, to manage the pain as well as protect the nerves from damage, new treatment options are being developed. Thus, all these factors, along with the increasing awareness, are driving the diabetic neuropathy treatment market growth.
The graph represents the comparison between the number of patients suffering from diabetes in the year of 2024 and 2045. It indicates that there will be a rise in the patients with diabetes in 2045. Hence, it increases the demand for new treatment as well as diagnostic options for the effective management of diabetic neuropathy along with diabetes. Thus, this in turn will ultimately promote the market growth.
Lack of Early Diagnosis
The diabetes neuropathy in most cases is not detected. This leads to the worsening of the conditions. It can cause permanent damage to the nerves, which in turn can cause more complications. Moreover, in some cases, the treatment can be ineffective due to its progression. Thus, to manage diabetic neuropathy, early detection is needed with proper management of the condition.
Increasing Gene Therapies
Most of the treatments of diabetic neuropathy focus on pain management and not on its treatment. Thus, the demand for effective treatment options rises. Therefore, the use of gene therapy, which focuses on the root cause of the neuropathy, is increasing. It helps to regenerate the damaged nerves as well as protect them. It can also be used in personalized treatment plans, depending on the patient’s genetic characteristics. Thus, this promotes the diabetic neuropathy treatment market growth.
For instance,
By disorder type, the peripheral neuropathy segment dominated the market in 2024. The peripheral neuropathy was detected in most of the patients due to its early diagnosis. Furthermore, the complications associated with it also contributed to the diabetic neuropathy treatment market growth.
By disorder type, the autonomic neuropathy segment is estimated to be the fastest growing at a notable CAGR during the forecast period. Due to increasing awareness, autonomic neuropathy is being effectively detected through early diagnosis. This, in turn, increases the demand for its management.
By drug class type, the non-steroidal anti-inflammatory drugs (NSAIDs) segment dominated the market in 2024. The NSAIDs were used in the management of the mild to moderate pain associated with diabetic neuropathy. At the same time, its availability and affordability enhanced the market growth.
By drug class type, the opioid segment is anticipated to grow significantly during the forecast period. The use of opioids is rising in the management of pain in severe conditions or when NSAIDs are ineffective in diabetic neuropathy. Thus, its demand is rising in the market.
By distribution channel type, the hospital pharmacies segment dominated the global diabetic neuropathy treatment market in 2024. The hospital pharmacies provided the advanced therapies for the treatment of diabetic neuropathy. Moreover, various treatment regimens were also offered in the severe cases, which resulted in promoting the market growth.
By distribution channel type, the online segment is predicted to grow significantly during the forecast period. The online distribution channel offers a wide range of products at reasonable prices. It also provides easy access and home deliveries, enhancing patient convenience and satisfaction.
North America dominated the diabetic neuropathy treatment market in 2024. North America consisted of well-developed industries along with skilled personnel, as well as technological advancements. This increased the number of innovations for the diagnosis and treatment of diabetic neuropathy, contributing to the market growth.
Due increasing demand for early diagnosis and treatment of diabetic neuropathy, the industries are focused on the development of the same. These are also supported by governmental funding or investments.
The industries in Canada are using the technologies to enhance diagnostic techniques using AI. Furthermore, new treatments are also being developed. This, in turn, increases the collaboration within the companies.
Europe is estimated to host the fastest-growing diabetic neuropathy treatment market during the forecast period. Europe is experiencing a rise in awareness due to increasing programs and campaigns about the early detection of diabetic neuropathy. Thus, this enhances the market growth.
Various programs are being conducted by the government as well as the private sector for the early diagnosis of neuropathy. This, in turn, increases the demand for the diagnosis and treatment of the same.
Due to the rising awareness through the campaigns, the demand for new and effective treatments is rising, along with the use of personalized medication. At the same time, the government is also supporting these awareness programs and campaigns.
Asia Pacific is expected to grow significantly in the diabetic neuropathy treatment market during the forecast period. The number of patients with diabetes is rising rapidly in the Asia Pacific. This increases the use as well as the demand for new diagnostic and treatment approaches for diabetic neuropathy. This promotes the market growth.
The number of patients with diabetes is increasing in China. Thus, this increases the production of new treatment approaches as well as research in the industries and institutes. This is further supported by the government.
India is facing rapid growth in diabetic patients, increasing the risk of diabetic neuropathy. Thus, with the help of government support, the healthcare sector is focusing on the development of new treatments as well as diagnostic methods for the same at affordable prices.
By Disorder Type
By Drug Class
By Distribution Channel
By Region
April 2025
April 2025
March 2025
March 2025